Zhongguo aizheng zazhi (Jan 2024)

Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)

  • Cancer Rehabilitation and Palliative Professional Committee of Shanghai Anti-Cancer Association , Cancer Drug Clinical Research Committee of Shanghai Anti-Cancer Association , Cancer Prevention and Clinical Research Committee of Chinese Aging Well Association

DOI
https://doi.org/10.19401/j.cnki.1007-3639.2024.01.008
Journal volume & issue
Vol. 34, no. 1
pp. 104 – 134

Abstract

Read online

Nausea and vomiting are common adverse reactions in tumor patients during anti-tumor therapy such as chemotherapy, radiotherapy, targeted therapy and immunotherapy. Although chemotherapy-induced nausea and vomiting (CINV) is the most common and the most intensively studied adverse event, radiation-induced nausea and vomiting (RINV), targeted therapy and immunotherapy-induced nausea and vomiting (TIINV) have also attracted more and more attention. Based on “Shanghai expert consensus on whole-process management of chemotherapy-induced nausea and vomiting (2018 edition)”, as well as new medical evidence of antineoplastic-induced nausea and vomiting (AINV) and experience of Shanghai experts in this field, the expert group finally developed “Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition)”. This consensus will guide doctors in Shanghai to standardize the whole-process management of AINV, and to ensure the treatment intensity and medical safety of patients.

Keywords